Compare Nomura Holdings Inc (NMR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Sana Biotechnology Inc — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Nomura Holdings Inc is far larger — about 31.4× Sana Biotechnology Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NMR | SANA | |
|---|---|---|
Market Cap | $27.46B | $873.84M |
Sector | Financials | Health |
52-Week High | $10.04 | $5.92 |
52-Week Low | $6.39 | $2.68 |
Dividend Yield | 3.45% | — |
Enterprise Value | — | $848.03M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
